Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics.
AMA J Ethics. 2021;23(5):E405-409. doi:
10.1001/amajethics.2021.405.
Rayner Kay Jin Tan, Jane Mingjie Lim, MSW, and Jeremiah Kah Wai Chan, MSc
Merits and drawbacks of U = U messaging are ethically and clinically complex, and drawbacks could harm patients in whom viral suppression is hard to achieve.
AMA J Ethics. 2021;23(5):E418-422. doi:
10.1001/amajethics.2021.418.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Stephanie L. Samuels, MD and Wilma C. Rossi, MD, MBE
When a parent resists a physician's recommendation for a pediatric patient, physician-parent partnering can promote the patient's best interest and help encourage lifestyle changes.
AMA J Ethics. 2018;20(12):E1126-1132. doi:
10.1001/amajethics.2018.1126